Servicio de Información Comunitario sobre Investigación y Desarrollo - CORDIS

Periodic Report Summary 1 - AD-VEC (Adenovirus Vector Technology: Next Generation Systems for Medical Therapy)

Project Objectives

The overarching aim of the AD-VEC consortium is to exploit the vast array of adenoviruses (AdVs) that exist in nature and harness their potential as vectors in medical applications to go beyond state-of-the-art through derivation and analysis of new vector technology. This will be achieved through improving our fundamental knowledge of adenovirus phylogeny, biology and pathology in order to explore them as vectors in areas of unmet clinical need such as cardiovascular disease, oncology and infectious disease.

The major objectives of AD-VEC are therefore:
1. Provision of adenovirus genomes from novel rare human and non-human adenoviruses and engineering of these genomes to develop high quality recombinant adenovirus vectors expressing reporter genes.
2. Detailed evaluation of novel adenovirus vectors with respect to infectivity, receptor usage, tropism, and the interaction with the blood and immune system.
3. Evaluation of novel vectors at the pre-clinical level in areas of unmet clinical need.

These three key objectives will enable excellence in adenovirus research amongst the AD-VEC consortium members through creating a synergistic and unique opportunity in this research field. The synergies are those that cross academic and industrial boundaries and create access to a pipeline of activity that will include basic virology, new assay development, novel preclinical models, pre-clinical manufacture and vector testing. This provides empowerment to the research teams through synergistic industry/academia collaborations developed towards a common goal, i.e. exploiting adenoviruses for medical therapy.

Progress towards Objectives
The project began on 1.3.13. A kick- off meeting took place in Zurich on 11th March 2013 and two further Management Board meetings have taken place; in Leiden on 25th Nov 2013 and in London on 26th Sep 2014 (the minutes and slides from the management board meetings are available if requested). All recruitments and secondments thus far have been enacted and effective apart from in the case of one beneficiary – Crucell – which was unsuccessful in finding a candidate to send on the planned secondment to CARHAS between M13-M18 (Gantt chart of original secondment planned is included in the annexes). All recruitments were approved by the Management Group. The precise timing of each secondment/ recruitment is provided in Table 2, correct as of end of Feb 2015. All partners are fully engaged, are in regular contact and reactive to any information and questions from the Coordinator, as well as between each partner at a scientific level. The only deviations on the scientific level are on the initial adenovirus serotypes to be "vectorised" following due diligence of adenovirus IP landscape at the start of the IAPP and the ability to grow certain viruses on defined cell types used for development of vectors (see WP2 update). The outcome of this is that WP2 is focusing on human adenoviruses 53 (HAdV-53) and 56 (HAdV-56) and simian adenovirus 17 (SAdV-17). WP3 has also identified novel human and non-human vectors which are now under investigation. Finally, the consortium agreement has been successfully concluded and signed by all programme beneficiaries. This periodic report summarises the progress made so far in each WP and provides an overview of the secondment and recruitment status of AD-VEC.

Main Results to-date
• Implementation of effective management strategies and communication.
• Implementation of effective scientific projects for all researchers.
• Focused scientific aims and objectives of projects through WP leaders with effective individual project management for each scientific project.
• An effective and functional website and dissemination strategy, including publication of an interesting podcast series with interviews with leading adenovirus experts from around the world.
• Effective mentoring of ERs and implementation of scientific projects and career plans.
• Successful mid-term review with excellent feedback for the programme.
• Consortium Agreement has been finalised and signed by all beneficiaries.

Expected Final Results and Impact
• Novel vectors for vaccine & gene therapy strategies.
• Novel viruses and their potential as new vectors for vaccine & gene therapy.
• A series of innovative and scientifically advancing ER projects that lead to original papers and reviews for ERs and PIs.
• Long term collaborative opportunities for adenovirus researchers both in academia and industry to foster innovative and high level adenovirus projects at the basic and translational level.
• Excellent career opportunities for ERs both within and outside adenovirus research, with a breadth of insights into maximising career opportunities and effective career decision making.
• Broad dissemination of novel Adenovirus knowledge acquired during the AD-VEC programme via significant public outreach efforts by ERs as Marie Curie ambassadors and PIs.

AD-VEC Consortium
The AD-VEC consortium consists of 5 partners, representing both research and academia and industry. The project partners are from the United Kingdom, The Netherlands, Hungary and Sweden. The IAPP is coordinated by Prof Andrew H Baker of the University of Glasgow, UK. The partners and their contact information can be found on the AD-VEC web pages:

AD-VEC IAPP began on 1st March 2013 and its entire duration is 48 months. AD-VEC was made possible by 100% grant funding from the European Commission’s Marie Curie Actions programme. The total eligible costs of ADVance amount to 1.95M €.

Network Identity
The following logo (figure 1) was created for the AD-VEC project and is used in all communication material, including posters, videos, leaflets, and website graphics as well as in official documents and reports: Figure 1 AD-VEC Logo

Network Website
A public website for AD-VEC was created and is hosted by the Institute for Veterinary Medical Research and is continually updated reflecting the latest network training events and publications. Figure 2 displays a screenshot of the main page. The url for the website is .
Figure 2 ADV

Reported by

United Kingdom
Síganos en: RSS Facebook Twitter YouTube Gestionado por la Oficina de Publicaciones de la UE Arriba